Myelin-water imaging and multi-shell diffusion-weighted imaging in adults with adrenoleukodystrophy
- PMID: 41079752
- PMCID: PMC12514751
- DOI: 10.1093/braincomms/fcaf371
Myelin-water imaging and multi-shell diffusion-weighted imaging in adults with adrenoleukodystrophy
Abstract
The pathophysiology of X-linked adrenoleukodystrophy (ALD) is not well-understood. New quantitative MRI (qMRI) sequences, such as myelin-water imaging (MWI) and multi-shell diffusion-weighted imaging (DWI), are non-invasive techniques that can investigate microstructural abnormalities in the brain. Using these techniques, this study investigated abnormal white matter of cerebral ALD (cALD) lesions and normal-appearing white matter (NAWM) in ALD and in controls. Adult participants were scanned on 3T MRI scanners. Fractional anisotropy (FA), axial diffusivity (AD) and radial diffusivity (RD) were measured with diffusion tensor imaging (DTI). The neurite density index (NDI) was established using neurite orientation dispersion and density imaging (NODDI). Myelin water fractions (MWF) were evaluated with multi-compartment relaxometry diffusion-informed MWI (MCR-DIMWI) and multi-echo T2-relaxation imaging with compressed sensing (METRICS). Measures were evaluated in 10 regions of interest (ROIs) in participants with and without cALD, and in controls. A total of 81 ALD participants (69% males, of whom 17 had cALD), and 21 controls were included. FA, NDI, MWFMETRICS and MWFMCR-DIMWI were significantly lower in lesions in the corpus callosum of cALD participants than in controls. FA, NDI and MWFMETRICS also significantly differentiated the NAWM of male, but not female, ALD participants from controls. FA and NDI had the largest effect sizes for males. In the NAWM, RD was increased, whereas AD was mostly unaffected. In a few NAWM regions, qMRI measures also differed between males with and without cALD. The NAWM of males with ALD contains microstructural abnormalities. Myelin and myelinated axons are impacted by ALD pathophysiology. These techniques have potential for clinical applications.
Keywords: biomarker; imaging; leukodystrophy; radiology; translational research.
© The Author(s) 2025. Published by Oxford University Press on behalf of the Guarantors of Brain.
Conflict of interest statement
M.S. van der Knaap is co-investigator regarding clinical trials for Calico (Vanishing White Matter) and for Ionis (Alexander disease trial). She is on patent P112686US00 ‘therapeutic effects of Guanabenz treatment in vanishing white matter’ and on patent P112686CA00 ‘the use of Guanabenz in the treatment of VWM’, both for the VU University Medical Center, Amsterdam, the Netherlands. She is the initiator and principal investigator of the Guanabenz trial (https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001438-25/NL), with permission of the Dutch national ethics committee (CCMO, NL61627.000.18). She received research grants from Calico and Ionis. M. Engelen is co-PI for Spur Therapeutics (CYGNET and PROPEL trials) and was co-PI for Minoryx (ADVANCE trial). He received research grants from Spur Therapeutics, Minoryx, Spolia and Autobahn Therapeutics.
Figures
References
-
- Schaumburg HH, Powers JM, Raine CS, et al. Adrenomyeloneuropathy: A probable variant of adrenoleukodystrophy. II. General pathologic, neuropathologic, and biochemical aspects. Neurology. 1977;27(12):1114–1119. - PubMed
-
- Igarashi M, Schaumburg HH, Powers J, Kishmoto Y, Kolodny E, Suzuki K. Fatty acid abnormality in adrenoleukodystrophy. J Neurochem. 1976;26(4):851–860. - PubMed
-
- Mosser J, Lutz Y, Stoeckel ME, et al. The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. Hum Mol Genet. 1994;3(2):265–271. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous